Jianming Xu
Jianming Xu led the Chinese stomach cancer trials of sintilimab, the ADC disitamab vedotin and other domestic drugs, in the country with the most stomach cancer patients.
Overview
Principal investigator of ORIENT-16 (sintilimab plus chemotherapy in first-line gastric cancer, JAMA 2023), of the pivotal disitamab vedotin gastric cancer study and of many Chinese phase 3 trials in gastric, colorectal and oesophageal cancer; a leading figure in the CSCO gastric cancer guidelines.
Pages like this
not linked directly; found by shared links- CompanyInnovent Biologics
Shares ORIENT-16, Sintilimab and the tag china.
- PersonMichael Yu (Yu De-Chao)
Shares Sintilimab and the tag china.
- TrialORIENT-11
Shares Sintilimab and the tag china.
- TrialORIENT-32
Shares Sintilimab and the tag china.
- InstitutionJiangsu Cancer Hospital
Shares Gastric & gastro-oesophageal junction cancer and the tag china.
- InstitutionRenji Hospital, Shanghai Jiao Tong University
Shares Gastric & gastro-oesophageal junction cancer and the tag china.
- ProductSavolitinib
Shares Gastric & gastro-oesophageal junction cancer and the tag china.
- PersonZonghai Li
Shares Gastric & gastro-oesophageal junction cancer and the tag china.